EGFR and non-small cell lung carcinoma: In 2016, the Food and Drug Administration (FDA) approved the Cobas® EGFR mutation test v2 (Roche) for blood and tissue analysis of EGFR mutations in patients with non-small-cell lung cancer (NSCLC).